| DISPLAY HOURS: 10:30 - 14:00 | A Review Of PERFOS In FDA And EMA Labelling Claims (2009-2019)  
Zorana Zupan, Nenad Medic, Eva Brown Hajdukova, Katja Rudell |
|-------------------------------|----------------------------------------------------------------|
| DISPLAY HOURS: 10:30 - 14:00 | Abbreviated HTA pathways, expediting patient access to novel treatments?  
James Campbell, Richard Macaulay |
| DISPLAY HOURS: 10:30 - 14:00 | Pan-EU clinical HTA – a non-uniform impact?  
James Campbell, Richard Macaulay |
| DISPLAY HOURS: 10:30 - 14:00 | Aim for the stars, reach the moon? A simple strategy to improve additional benefit outcomes in Germany?  
Richard Macaulay, Anne Jakel, Ikhlaas Kasli, Andrea Berardi |
| DISPLAY HOURS: 10:30 - 14:00 | Do Spanish TPRs affect the national pricing and reimbursement of drugs?  
Richard Macaulay, Andrea Berardi, Raquel Fernandez DaCosta |
| DISPLAY HOURS: 10:30 - 14:00 | Ready for PRIME time? Have EMA prime designations supported accelerated regulatory approval and patient access?  
Ben Cieply, Richard Macaulay, Daniel Sutcliffe, George Wang |
| DISPLAY HOURS: 10:30 - 14:00 | The not-NICE access pathway: NHS England specialised commissioning  
Cornelia Roibu, Hristina Ivanova, Richard Macaulay |
| DISPLAY HOURS: 10:30 - 14:00 | Managed entry agreements for prescription drugs in Sweden- the company perspective  
Jonas Lindblom, Karolina Antonov |
| DISPLAY HOURS: 10:30 - 14:00 | Managed entry agreements for prescription drugs in Sweden  
Emma Medin, Karolina Antonov |
| DISPLAY HOURS: 10:30 - 14:00 | Patient-Reported Outcomes Used In Clinical Trials Of Systemic Lupus Erythematosus: A Review Of Suitability For FDA Labelling Claims  
Nenad Medic, Zorana Zupan, Eva Brown Hajdukova, Katja Rudell |
| DISPLAY HOURS: 15:30 - 19:00 | Better late than never: the dynamics of NICE decision-making under the new model of the CDF  
Adam Hall, LokWan Liu, Richard Macaulay |
| DISPLAY HOURS: 15:30 - 19:00 | Are NICE appraisal committees being consistent in their implementation of the End Of Life criterion?  
Richard Macaulay, Urvi Khatri |
| DISPLAY HOURS: 15:30 - 19:00 | Assessment Of Surrogacy Outcomes For Overall Survival In Oncology Based On Nice Appraisals And Post-Appraisal Evidence  
Tray Brown, Mirko Von Hein |
| DISPLAY HOURS: 15:30 - 19:00 | A Landmark Response Analysis To Determine Cost-Effectiveness Of Third-Line Nivolumab Monotherapy For Small Cell Lung Cancer  
Caitlin Smare, Kiran Dave |
| DISPLAY HOURS: 15:30 - 19:00 | A Partitioned Survival Model To Determine Cost-Effectiveness Of Third-Line Nivolumab Monotherapy For Small Cell Lung Cancer  
Caitlin Smare, Kiran Dave |
| DISPLAY HOURS: 15:30 - 19:00 | Accelerating Early Cost-Effectiveness Modeling In Oncology Using An Indication-Agnostic Web-Based Platform: A Retrospective Case Study Of Nivolumab Pre-Treated Metastatic Small-Cell Lung Cancer Population  
Elise Wu, Andrea Berardi, Malin Berling, Caitlin Smare, Yong Yuan, Samuel Wagner |
| DISPLAY HOURS: 15:30 - 19:00 | What Is Worth Knowing At Early Development? Value Of Information Analysis Using An Indication-Agnostic Web-Based Platform: A Case Study  
Elise Wu, Andrea Berardi, Malin Berling, Caitlin Smare, Yong Yuan, Samuel Wagner |
| DISPLAY HOURS: 15:30 - 19:00 | Cost-Effectiveness Of Nivolumab For The Adjuvant Treatment Of Patients With Melanoma With Involvement Of Lymph Nodes Or Metastatic Disease Who Have Undergone Complete Resection In Greece  
Margarida Augusto, Siguroli Teitsson, Isabella Orsini |
| DISPLAY HOURS: 15:30 - 19:00 | Cost-Effectiveness Of Nivolumab As Adjuvant Treatment Of Melanoma In Adults With Involvement Of Lymph Nodes Or Metastatic Disease Who Have Undergone Complete Resection In The Italian Setting  
Margarida Augusto, Siguroli Teitsson, Isabella Orsini |
| DISPLAY HOURS: 15:30 - 19:00 | A Cost-Utility Analysis Of Nivolumab In The Adjuvant Treatment Of Melanoma In France  
Margarida Augusto, Siguroli Teitsson |
| DISPLAY HOURS: 15:30 - 19:00 | Cost-Effectiveness Of Nivolumab As Adjuvant Treatment Of Melanoma In Adults With Involvement Of Lymph Nodes Or Metastatic Disease Who Have Undergone Complete Resection In Belgium  
Margarida Augusto, Siguroli Teitsson, Isabella Orsini |
| DISPLAY HOURS: 15:30 - 19:00 | Cost-Effectiveness Of Nivolumab For The Adjuvant Treatment Of Patients With Melanoma With Involvement Of Lymph Nodes Or Metastatic Disease Who Have Undergone Complete Resection: An Analysis From A Swiss Healthcare System Perspective  
Margarida Augusto, Siguroli Teitsson, Isabella Orsini |
| DISPLAY HOURS: 15:30 - 19:00 | Validation Of Predicted Survival Estimates From Previous Data Cuts Of The Phase Iii Checkmate 025 Study In Advanced Renal Cell Carcinoma  
Siguroli Teitsson, Orban Holdgate |
| DISPLAY HOURS: 15:30 - 19:00 | A cost-utility analysis of nivolumab in the adjuvant treatment of melanoma in France  
Margarida Augusto, Siguroli Teitsson |
| DISPLAY HOURS: 15:30 - 19:00 | Value assessment of HTA decisions for PD-1/PDL-1 inhibitors in oncology: a NICE perspective  
Arushi Bamrara, Namita Mishra, Shweta Takyar |
| DISPLAY HOURS: 15:30 - 19:00 | Estimating the burden of salivary gland cancer in Nordic countries: a predictive analysis using time series analysis methods  
Shubhram Pandey, Priyanka Singh, Jitender Takyar, Kashif Siddiqui, Jackie Vanderpuye-Orgle |
| DISPLAY HOURS: 15:30 - 19:00 | Estimating the burden of malignant haematopoietic cancers in Nordic countries: a predictive analysis using time series analysis methods  
Barinder Singh, Meenu Verma, Sakshi Sharma, Shruthi Bethi, Sheetal Sharma |
| DISPLAY HOURS: 15:30 - 19:00 | Breast cancer scanning using somatostatin analogues: Systematic review and meta-analyse  
Akanksha Sharma, Shubhram Pandey, Kashif Siddiqui, Jackie Vanderpuye-Orgle, Divesh Singla |
<table>
<thead>
<tr>
<th>DISPLAY HOURS: 15:30 - 19:00</th>
<th>Disease Specific Patient-Reported Outcome (PRO) Instruments For Hematologic Malignancies (HM) Eva Brown Hajdukova, Nenad Medic, Zorana Zupan, Katja Rudell</th>
</tr>
</thead>
<tbody>
<tr>
<td>FORUM</td>
<td>12:30 - 13:45 New Frontiers: Valuing COA data and guiding principles for RWE Katja Rudell, Angela Rylands, Bryan Bennett, Ana Maria Rodriguez, L Doward</td>
</tr>
<tr>
<td>BREAKOUT SESSION</td>
<td>12:30 - 13:45 Demystifying Machine Learning: Why Being Open To It? When We Found It Useful Helene Karcher, Jackie Vanderpuye-Orgle</td>
</tr>
<tr>
<td><strong>Tuesday, 5 November 2019</strong></td>
<td><strong>POSTER PRESENTATIONS</strong></td>
</tr>
<tr>
<td>DISPLAY HOURS: 10:30 - 14:00</td>
<td>Unlocking the access challenges to COPD Daniela Palazzolo, Ikhlaas Kasli, Daniel Sutcliffe, Richard Macaulay</td>
</tr>
<tr>
<td>DISPLAY HOURS: 10:30 - 14:00</td>
<td>Will CAR-T cell therapies change how drugs are priced and reimbursed? Richard Macaulay, Ikhlaas Kasli</td>
</tr>
<tr>
<td>DISPLAY HOURS: 10:30 - 14:00</td>
<td>Vaccine reimbursement trends and associated challenges in Europe – A systematic literature review (SLR) Sheetal Sharma, Jitender Takyar, Vinay Pandey, Varun Chopra, Ashlin Alexander</td>
</tr>
<tr>
<td>DISPLAY HOURS: 10:30 - 14:00</td>
<td>Cost Effectiveness Of As-Needed Budesonide/Formoterol Vs Low-Dose ICS Maintenance Therapy In Mild Asthma Patients: A UK Perspective Caitlin Smare, Kirsty Hounsell</td>
</tr>
<tr>
<td>DISPLAY HOURS: 15:45 - 19:00</td>
<td>Assessing the future- evaluation of the initial HTA assessments of ATMPs in the Nordics Anja Wikström, Jonas Lindblom, Marcus Hultberg, Emma Medin</td>
</tr>
<tr>
<td>DISPLAY HOURS: 15:45 - 19:00</td>
<td>Is there regional variation in worse and slower cost/QALY HTA outcomes for combination products involving two vs. one manufacturer? Erika Turkstra, LokWan Liu, Richard Macaulay</td>
</tr>
<tr>
<td>DISPLAY HOURS: 15:45 - 19:00</td>
<td>Unlocking access for transformational CAR-T cell and gene therapies. Are biosimilars the key? Hristina Ivanova, Richard Macaulay</td>
</tr>
</tbody>
</table>
| DISPLAY HOURS: 15:45 - 19:00 | Navigating divergence: accommodating the multitude of new payer bodies in emerging markets  
Richard Macaulay, Hristina Ivanova, Nenad Medic |
| --- | --- |
| DISPLAY HOURS: 15:45 - 19:00 | The Danish medicine council’s process of assessing new hospital medicines- an analysis of decisions 2017-2019  
Martin Virhage, Emma Medin |
| 15:45 - 16:45 | Do we still need randomized controlled trials?  
Lucinda Orsini, William Crown, Leanne Larson, Jeroen P Jansen |
| 08:30 - 09:30 | Subscription-Based Model for Drug Reimbursement – a Fad or the Future?  
Richard Macaulay, Andrew Walker, Erika Turkstra, Diar Fattah |
| DISPLAY HOURS: 09:30 - 14:00 | A new major market access challenge - keeping the ROI window open?  
Richard Macaulay, George Wang, Ikhlaas Kasli |
| DISPLAY HOURS: 09:30 - 14:00 | Reimbursement of ultra-orphan medicines: a new best-practice framework?  
Richard Macaulay, Urvi Khatri |
| DISPLAY HOURS: 09:30 - 14:00 | The HST test: good, better, best?  
Richard Macaulay, LokWan Liu, Erika Turkstra |
| DISPLAY HOURS: 09:30 - 14:00 | Landscape assessment of new therapies and Key HTA considerations in Alzheimer’s disease – Insights for reimbursement submissions  
Shweta Takyar, Simarjeet Kaur, Jitender Takyar, Arju Dhawan |
| DISPLAY HOURS: 09:30 - 14:00 | Efficacy of CFTR modulators against pulmonary exacerbation in cystic fibrosis: A systematic review and network meta-analysis  
Jitender Takyar, Kajal Thapa, Astha Jain, Akanksha Sharma |
| DISPLAY HOURS: 09:30 - 14:00 | Economic and humanistic burden in Huntington’s disease  
Gagandeep Kaur, Pankaj Rai, Sheetal Sharma |